Akari Therapeutics PLC
AKTX
NASDAQ
Biotechnology
$7.54
USD
+0.54 (+7.71%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.01M
Volume 164.1K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-28.05M
TTM
-56.4%
YoY
Operating Cash Flow
$-10.91M
TTM
-2.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.7 | 2.5 | 2.0 | 2.1 | 2.2 |
Other Operating Expenses | 0.0 | 0.0 | 5.2 | 0.0 | 12.1 |
Total Operating Expenses | 3.5 | 3.1 | 7.4 | 3.2 | 15.8 |
Operating Income | -3.5 | -3.1 | -7.4 | -3.2 | -15.8 |
EBITDA | -3.5 | -3.1 | -2.2 | -3.2 | -3.6 |
Other Income / Expense | -0.1 | 1.3 | 0.0 | -1.3 | 0.5 |
Total Other Income / Expense | -0.2 | 1.2 | -0.1 | -2.0 | 0.4 |
Income Before Income Taxes | -3.7 | -1.9 | -7.5 | -5.2 | -15.3 |
Income Taxes | 0.0 | 0.0 | -1.1 | 0.1 | -0.9 |
Net Income | -3.7 | -1.9 | -6.4 | -5.3 | -14.5 |
Consolidated Net Income / Loss | -3.7 | -1.9 | -6.4 | -5.3 | -14.5 |
Net Income Attributable to Common Shareholders | -3.7 | -1.9 | -6.4 | -5.3 | -14.5 |
Basic EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Basic Shares Outstanding | 54,588.3M | 1,573.6M | 1,633.2M | 86,454.1M | 118,757.0M |
Diluted Shares Outstanding | 54,588.3M | 1,573.6M | 1,633.2M | 86,454.1M | 118,757.0M |